Formulation and evaluation of controlled release matrix Transdermal patches of Metoprolol Succinate
The controlled release matrix transdermal patches of Metoprolol succinate were prepared by the method of solvent casting technique employing ‘O’ shape ring placed on a glass surface as substrate by using different polymers like HPMC K4M, PVP K30 and Eudragit RL100. The dibutylphthalate (30%w/w) used as plasticizer and permeation enhancer, whereas aluminium foil served as a baking membrane. The prepared matrix transdermal patches of Metoprolol succinate was evaluated for physicochemical characteristics like thickness, weight, flatness, folding endurance, surface pH, percentage moisture absorption, percentage moisture loss, water vapor transmission rate and drug content. The satisfactory results were obtained in all prepared formulation and based on the results MP14 (HPMCK4M-71.25mg, PVP K30-4.75mg and Eudragit RL100-19mg) was the best one when compared to other. The in-vitro kinetics shows the zero order drug release followed by non-Fickian diffusion mechanism. The in-vivo kinetics was shows in the extent of bioavailability and in the rate of absorption. The optimized formulation were stable at accelerated conditions with level of significance P>0.05. Good correlation was observed between in-vitro and ex-vivo, in-vitro and in-vivo profile revealed the ability of the formulation to reproduce the in-vitro permeation pattern through the rat abdominal skin and rabbit. Hence the controlled release matrix transdermal patches of Metoprolol succinate which are used mainly in minimizing dose and help to improve the patient compliance and Metoprolol succinate is a drug of choice for delivery through the control release via matrix transdermal patches.
PDF Downloaded: 1